We are live on ! Find out more
KDNY

Chinook Therapeutics, Inc. Common Stock
KDNY

Delisted

KDNY was delisted on the 10th of August, 2023.

Back to rankings

2 hedge funds and large institutions have $0 invested in Chinook Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 181 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 185 → 2 (-183)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $2.24B → $0 (-$2.24B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 181

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-183
Holders Change %
-98.92%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
181
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
-$198M
2
FLSM
Frazier Life Sciences Management
California
-$167M
3
BlackRock
BlackRock
New York
-$164M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$113M
5
State Street
State Street
Massachusetts
-$112M
Name Holding Trade Value Shares
Change 		Change in
Stake
RAM
176
Riggs Asset Management
Pennsylvania
– -$2.5K -65 Closed
SWM
177
Spire Wealth Management
Virginia
– -$1.15K -30 Closed
BAM
178
Bellevue Asset Management
Washington
– -$1.04K -27 Closed
BIA
179
Bell Investment Advisors
California
– -$807 -21 Closed
PA
180
Parallel Advisors
California
– -$828 -21 -81%
LC
181
Lindbrook Capital
California
– -$461 -12 Closed
4 5 6 7
8

KDNY Hedge Fund Activity: Q3 2023 in Review

2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2023, worth a combined $0 — down 100% from $2.24B a quarter earlier.

Sellers outnumbered buyers: 181 funds closed out of KDNY and 0 opened new positions — a net loss of 181 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Samsara BioCapital, exiting entirely with an estimated $198M sold.

  • 2 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2023, down from 185 in Q2 2023.
  • Funds reported $0 of Chinook Therapeutics, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2023 and 181 closed out, a net change of -181 holders.
  • The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2023 was Samsara BioCapital, an estimated $198M sold.

Based on aggregated 13F filings for Q3 2023.